Humanigen Inc
HGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-2,213,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | -1.05 |
| Outstanding Shares | 1,190,801 |
Return
| Return on Equity | 107.20% |
|---|---|
| Return on Assets | -1041.89% |
| Return on Invested Capital | 107.95% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -1.3 |
| Enterprise Value to EBIT | 0.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.4 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Humanigen Inc
10 employees
CEO: Cameron Durrant Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's ...